Services
KMT Hepatech, Inc. is comprised of world class researchers and expert clinicians in the fields of viral hepatitis, liver disease and liver transplantation. As a result, our team is able to contribute significant scientific and clinical knowledge to aid in your product development efforts.
Our facilities include offices, a biochemical laboratory, and an animal facility.
Our experienced team of highly skilled and knowledgeable scientific staff is able to design and execute a wide range of studies to meet your unique product development requirements. Specific categories of scientific evaluations performed by KMT Hepatech, Inc. include:
-
PK / tolerability evaluations
-
Proof of concept: vehicle vs drug treatment
-
Dose response study
-
Combination therapy study
-
Head-to-head comparison of different drugs
-
In vivo resistance evaluation
-
Prediction of dosage ranges for clinical trials
-
Evaluation of preventive therapies including passive immunotherapy
-
Exploration of drug metabolism by human hepatocytes
-
Human lipoprotein metabolism and therapies
-
Other liver-affinity pathogen studies
Our scientists work closely with your scientific team, utilizing a collaborative approach to develop an evaluation strategy that meets your priorities and needs. We will customize studies to answer your most urgent questions related to pre-clinical evaluation of a potential product and to provide you with the highest possible level of assurance that your lead candidate is efficacious prior to entering clinical trials.
For each client relationship, a joint Client – KMT Hepatech, Inc. Research Steering Committee monitors progress and directs the research agenda. This ensures the client achieves their research objectives, according to their timeline and their budget utilizing the KMT Mouse™.
Hepatitis C
Approximately 200 million people worldwide suffer with Hepatitis C and risk development of fibrosis, cirrhosis, liver failure and cancer. Half do not respond to current therapy and face liver transplant or death.
Hepatitis C only infects humans or chimpanzees, so finding a test subject for the development of therapies and vaccines is extremely difficult, time constraining and with the chimpanzee model, very expensive.
KMT MouseTM platform technology is a cost effective animal model that contributes important advantages to research on Hepatitis C and other liver related diseases.